Codexis Inc (CDXS)

$2.69 +0.11 (4.05%)
Market Cap 233.79M
Revenue (ttm) 59.35M
Net Income (ttm) -65.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -109.99%
Debt to Equity Ratio 0.71
Volume 426,000
Avg Vol 786,200
Day's Range N/A - N/A
Shares Out 90.27M
Stochastic %K 71%
Beta 2.50
Analysts Strong Sell
Price Target $7.08

Company Profile

Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with A...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 421 8100
Address:
200 Penobscot Drive, Redwood City, United States
Jiggitus23
Jiggitus23 Oct. 24 at 8:28 PM
$CDXS sideways is so damn boring
1 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 24 at 4:06 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $CDXS Current Share Price: $2.62 Contracts: $CDXS March 20, 2026 $5 Calls Scale in: $0.20- $0.25 Scale out: $0.32-$0.41 Can Easily Capture: 60% ROI Blended DTE: 148 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
djohndjohn
djohndjohn Oct. 23 at 6:55 PM
$CDXS Interesting date for Earnings release and CC. I thought it would be Nov 13th but they pick Nov 6th. One day after the big Webinar with Bachem and before TIDES. Anyone think we may get some big news from Bachem about Vista, CA or better yet Building K?
1 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 23 at 6:41 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $CDXS Current Share Price: $2.56 Contracts: $CDXS March 20, 2026 $5 Calls Scale in: $0.23- $0.28 Scale out: $0.35-$0.45 Can Easily Capture: 60% ROI Blended DTE: 149 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Levis6
Levis6 Oct. 22 at 3:24 PM
$CDXS
0 · Reply
BillionerOfKing
BillionerOfKing Oct. 22 at 2:55 PM
$CDXS Current Stock Price: $2.64 Contracts to trade: $2.5 CDXS Nov 21 2025 Call Entry: $0.30 Exit: $0.41 ROI: 38% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Fingerlickengood
Fingerlickengood Oct. 22 at 2:26 PM
$CDXS $DHR Interesting! https://www.aldevron.com/catalog-products/free-sample?utm_campaign=9437057-mrna-vx-tx&utm_term=codex-gmp-grade&utm_content=348143505&utm_medium=social&utm_source=linkedin&hss_channel=lcp-151339
0 · Reply
10xMoonstocks
10xMoonstocks Oct. 21 at 5:27 PM
$CDXS Where did you go??? You sure got quiet all of the sudden. Did the recent green days/month put you back in your place 🤡.
1 · Reply
Jiggitus23
Jiggitus23 Oct. 20 at 6:12 PM
$CDXS as long as trump doesnt doesn’t do something crazy, I feel good about this.
2 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 20 at 2:15 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $CDXS Current Share Price: $2.65 Contracts: $CDXS March 20, 2026 $5 Calls Scale in: $0.25- $0.30 Scale out: $0.39-$0.50 Can Easily Capture: 60% ROI Blended DTE: 152 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Latest News on CDXS
Codexis to Report Third Quarter 2025 Financial Results on November 6

Oct 23, 2025, 7:05 AM EDT - 2 days ago

Codexis to Report Third Quarter 2025 Financial Results on November 6

Codexis to Participate in Cantor Global Healthcare Conference

Aug 28, 2025, 9:00 AM EDT - 2 months ago

Codexis to Participate in Cantor Global Healthcare Conference

Codexis, Inc. (CDXS) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 7:57 PM EDT - 2 months ago

Codexis, Inc. (CDXS) Q2 2025 Earnings Call Transcript

Codexis Reports Second Quarter 2025 Financial Results

Aug 13, 2025, 4:05 PM EDT - 2 months ago

Codexis Reports Second Quarter 2025 Financial Results

Codexis to Report Second Quarter 2025 Financial Results on August 13

Jul 30, 2025, 4:05 PM EDT - 3 months ago

Codexis to Report Second Quarter 2025 Financial Results on August 13

Codexis' Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA

May 22, 2025, 7:00 AM EDT - 5 months ago

Codexis' Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA

Codexis to Participate in Jefferies Global Healthcare Conference

May 21, 2025, 4:05 PM EDT - 5 months ago

Codexis to Participate in Jefferies Global Healthcare Conference

Codexis, Inc. (CDXS) Q1 2025 Earnings Call Transcript

May 14, 2025, 6:50 PM EDT - 5 months ago

Codexis, Inc. (CDXS) Q1 2025 Earnings Call Transcript

Codexis Reports First Quarter 2025 Financial Results

May 14, 2025, 4:05 PM EDT - 5 months ago

Codexis Reports First Quarter 2025 Financial Results

Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting

May 7, 2025, 7:00 AM EDT - 6 months ago

Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting

Codexis to Report First Quarter 2025 Financial Results on May 14

Apr 30, 2025, 4:05 PM EDT - 6 months ago

Codexis to Report First Quarter 2025 Financial Results on May 14

Codexis Announces Byron Dorgan to Retire from Board of Directors

Apr 9, 2025, 5:00 PM EDT - 7 months ago

Codexis Announces Byron Dorgan to Retire from Board of Directors

Codexis Announces New Employment Inducement Grants

Mar 7, 2025, 4:05 PM EST - 8 months ago

Codexis Announces New Employment Inducement Grants

Codexis, Inc. (CDXS) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 10:20 PM EST - 8 months ago

Codexis, Inc. (CDXS) Q4 2024 Earnings Call Transcript

Codexis to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27th

Feb 13, 2025, 4:05 PM EST - 9 months ago

Codexis to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27th

Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board

Feb 6, 2025, 4:05 PM EST - 9 months ago

Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board

Codexis Appoints Christos Richards to Board of Directors

Jan 16, 2025, 4:05 PM EST - 10 months ago

Codexis Appoints Christos Richards to Board of Directors

Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 4:05 PM EST - 1 year ago

Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference

Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics

Nov 14, 2024, 4:05 PM EST - 1 year ago

Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics

Codexis Announces Appointment of Raymond De Vré, PhD, to Board of Directors

Nov 12, 2024, 4:05 PM EST - 1 year ago

Codexis Announces Appointment of Raymond De Vré, PhD, to Board of Directors

Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics

Nov 11, 2024, 4:05 PM EST - 1 year ago

Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics

Codexis to Participate in Upcoming Healthcare Conferences

Nov 4, 2024, 4:05 PM EST - 1 year ago

Codexis to Participate in Upcoming Healthcare Conferences

Codexis, Inc. (CDXS) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 10:48 PM EDT - 1 year ago

Codexis, Inc. (CDXS) Q3 2024 Earnings Call Transcript

Codexis Announces Three siRNA Manufacturing Data Presentations at TIDES Europe Annual Meeting

Oct 24, 2024, 4:05 PM EDT - 1 year ago

Codexis Announces Three siRNA Manufacturing Data Presentations at TIDES Europe Annual Meeting

Codexis to Report Third Quarter 2024 Financial Results on October 31

Oct 10, 2024, 4:05 PM EDT - 1 year ago

Codexis to Report Third Quarter 2024 Financial Results on October 31

Codexis Increases Cash Reserves and Enhances Management Team to Fuel Growth of Company

Oct 2, 2024, 4:05 PM EDT - 1 year ago

Codexis Increases Cash Reserves and Enhances Management Team to Fuel Growth of Company

Codexis Licenses Genomics Life Science Enzyme Portfolio to Alphazyme LLC, part of Maravai LifeSciences

Oct 1, 2024, 7:05 AM EDT - 1 year ago

Codexis Licenses Genomics Life Science Enzyme Portfolio to Alphazyme LLC, part of Maravai LifeSciences

Codexis to Participate in Enzymatic Synthesis Presentations at RNA Leaders Annual Meeting

Aug 20, 2024, 4:05 PM EDT - 1 year ago

Codexis to Participate in Enzymatic Synthesis Presentations at RNA Leaders Annual Meeting

Codexis Publishes FY2023 Sustainability Disclosures

Aug 15, 2024, 4:05 PM EDT - 1 year ago

Codexis Publishes FY2023 Sustainability Disclosures

Codexis, Inc. (CDXS) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 11:01 PM EDT - 1 year ago

Codexis, Inc. (CDXS) Q2 2024 Earnings Call Transcript

Codexis to Report Second Quarter 2024 Financial Results on August 8

Jul 18, 2024, 4:05 PM EDT - 1 year ago

Codexis to Report Second Quarter 2024 Financial Results on August 8

Codexis Finalizes Purchase Agreement with Crosswalk Therapeutics for Gene Therapy Assets

Jul 1, 2024, 4:05 PM EDT - 1 year ago

Codexis Finalizes Purchase Agreement with Crosswalk Therapeutics for Gene Therapy Assets

Codexis to Participate in TD Cowen 2nd Annual Sustainability Week

May 20, 2024, 4:05 PM EDT - 1 year ago

Codexis to Participate in TD Cowen 2nd Annual Sustainability Week

Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting

May 14, 2024, 6:00 AM EDT - 1 year ago

Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting

Codexis, Inc. (CDXS) Q1 2024 Earnings Call Transcript

May 2, 2024, 8:24 PM EDT - 1 year ago

Codexis, Inc. (CDXS) Q1 2024 Earnings Call Transcript

Codexis to Report First Quarter 2024 Financial Results on May 2

Apr 18, 2024, 4:05 PM EDT - 1 year ago

Codexis to Report First Quarter 2024 Financial Results on May 2

Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board

Apr 11, 2024, 7:05 AM EDT - 1 year ago

Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board

Codexis, Inc. (CDXS) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 10:39 PM EST - 1 year ago

Codexis, Inc. (CDXS) Q4 2023 Earnings Call Transcript

Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Feb 28, 2024, 4:05 PM EST - 1 year ago

Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche

Feb 26, 2024, 4:05 PM EST - 1 year ago

Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche

Codexis to Participate in TD Cowen 44th Annual Health Care Conference

Feb 26, 2024, 8:05 AM EST - 1 year ago

Codexis to Participate in TD Cowen 44th Annual Health Care Conference

Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board

Feb 20, 2024, 8:05 AM EST - 1 year ago

Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board

Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28

Feb 14, 2024, 4:05 PM EST - 1 year ago

Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28

Codexis Secures $40 Million in Strategic Financing Deal with Innovatus Capital Partners to Further Strengthen Cash Position Ahead of Key Milestones

Feb 13, 2024, 4:05 PM EST - 1 year ago

Codexis Secures $40 Million in Strategic Financing Deal with Innovatus Capital Partners to Further Strengthen Cash Position Ahead of Key Milestones

seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General Meeting

Feb 1, 2024, 4:05 PM EST - 1 year ago

seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General Meeting

Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108

Dec 27, 2023, 8:30 AM EST - 1 year ago

Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108

Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA Polymerase

Dec 13, 2023, 4:06 PM EST - 2 years ago

Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA Polymerase

Codexis Announces Achievement of Gram-scale Synthesis with its ECO Synthesis™ Platform

Dec 13, 2023, 4:05 PM EST - 2 years ago

Codexis Announces Achievement of Gram-scale Synthesis with its ECO Synthesis™ Platform

Codexis KOL Event Highlights Significant Need for an Enzymatic Route of Synthesis in RNAi Therapeutics Manufacturing

Dec 11, 2023, 7:05 AM EST - 2 years ago

Codexis KOL Event Highlights Significant Need for an Enzymatic Route of Synthesis in RNAi Therapeutics Manufacturing

Codexis to Host Virtual KOL Event on its ECO Synthesis™ Platform and the Future of RNAi Therapeutics Manufacturing on December 8, 2023

Nov 28, 2023, 4:05 PM EST - 2 years ago

Codexis to Host Virtual KOL Event on its ECO Synthesis™ Platform and the Future of RNAi Therapeutics Manufacturing on December 8, 2023

Jiggitus23
Jiggitus23 Oct. 24 at 8:28 PM
$CDXS sideways is so damn boring
1 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 24 at 4:06 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $CDXS Current Share Price: $2.62 Contracts: $CDXS March 20, 2026 $5 Calls Scale in: $0.20- $0.25 Scale out: $0.32-$0.41 Can Easily Capture: 60% ROI Blended DTE: 148 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
djohndjohn
djohndjohn Oct. 23 at 6:55 PM
$CDXS Interesting date for Earnings release and CC. I thought it would be Nov 13th but they pick Nov 6th. One day after the big Webinar with Bachem and before TIDES. Anyone think we may get some big news from Bachem about Vista, CA or better yet Building K?
1 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 23 at 6:41 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $CDXS Current Share Price: $2.56 Contracts: $CDXS March 20, 2026 $5 Calls Scale in: $0.23- $0.28 Scale out: $0.35-$0.45 Can Easily Capture: 60% ROI Blended DTE: 149 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Levis6
Levis6 Oct. 22 at 3:24 PM
$CDXS
0 · Reply
BillionerOfKing
BillionerOfKing Oct. 22 at 2:55 PM
$CDXS Current Stock Price: $2.64 Contracts to trade: $2.5 CDXS Nov 21 2025 Call Entry: $0.30 Exit: $0.41 ROI: 38% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Fingerlickengood
Fingerlickengood Oct. 22 at 2:26 PM
$CDXS $DHR Interesting! https://www.aldevron.com/catalog-products/free-sample?utm_campaign=9437057-mrna-vx-tx&utm_term=codex-gmp-grade&utm_content=348143505&utm_medium=social&utm_source=linkedin&hss_channel=lcp-151339
0 · Reply
10xMoonstocks
10xMoonstocks Oct. 21 at 5:27 PM
$CDXS Where did you go??? You sure got quiet all of the sudden. Did the recent green days/month put you back in your place 🤡.
1 · Reply
Jiggitus23
Jiggitus23 Oct. 20 at 6:12 PM
$CDXS as long as trump doesnt doesn’t do something crazy, I feel good about this.
2 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 20 at 2:15 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $CDXS Current Share Price: $2.65 Contracts: $CDXS March 20, 2026 $5 Calls Scale in: $0.25- $0.30 Scale out: $0.39-$0.50 Can Easily Capture: 60% ROI Blended DTE: 152 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 17 at 5:11 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $CDXS Current Share Price: $2.64 Contracts: $CDXS March 20, 2026 $5 Calls Scale in: $0.18- $0.22 Scale out: $0.28-$0.36 Can Easily Capture: 60% ROI Blended DTE: 154 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Levis6
Levis6 Oct. 16 at 2:50 PM
$CDXS maybe but that don’t change the fact that is going down.
2 · Reply
10xMoonstocks
10xMoonstocks Oct. 16 at 1:27 PM
$CDXS You've got to be kidding me? You are actually making a bearish comment when they cashed out a total of $31K in stock, which was a planned sell for tax purposes?? You are a freaking joke
0 · Reply
Levis6
Levis6 Oct. 16 at 11:48 AM
$CDXS CDXS In recent transactions involving Codexis stock, both CTO Alison Moore and CFO Georgia Erbez have sold 6,239 shares each. The total value of each sale amounted to $15,597, reflecting a coordinated move by the company’s top executives. when the heads of their own company starts to sell their own assets, its a strong sign that this will go deep 🙂
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 16 at 10:45 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $CDXS Current Share Price: $2.74 Contracts: $CDXS March 20, 2026 $5 Calls Scale in: $0.26- $0.32 Scale out: $0.41-$0.52 Can Easily Capture: 60% ROI Blended DTE: 155 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
BK217
BK217 Oct. 16 at 12:26 AM
$CDXS time to buy. Retard Levi is short
0 · Reply
Jiggitus23
Jiggitus23 Oct. 15 at 8:23 PM
$CDXS maybe, just maybe, we may see some good price action soon. I’m ready.
0 · Reply
Bondra
Bondra Oct. 15 at 6:43 PM
$CDXS Yeah no - this Will not hold.
1 · Reply
Levis6
Levis6 Oct. 14 at 3:50 PM
$CDXS
0 · Reply
Trq2507
Trq2507 Oct. 14 at 1:37 PM
$CDXS
1 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 13 at 7:53 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $CDXS Current Share Price: $2.59 Contracts: $CDXS March 20, 2026 $5 Calls Scale in: $0.19- $0.23 Scale out: $0.29-$0.38 Can Easily Capture: 60% ROI Blended DTE: 158 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Levis6
Levis6 Oct. 13 at 3:27 PM
$CDXS
0 · Reply